Formulation & InVitro Evaluation of Controlled Release Tablets of Oxcarbazepine

N.Phrudvish; T.Malyadri; Ch.Saibabu

doi:10.46956/ijihd.vi.161

N.Phrudvish Department of Pharmaceutics, M.L. College of Pharmacy, S. Konda-523101
T.Malyadri Assistant professor, Department of Pharmaceutics, M.L. College of Pharmacy, S. Konda-523101
Ch.Saibabu Head, Department of Pharmaceutics, M.L. College of Pharmacy, S. Konda-523101

DOI https://doi.org/10.46956/ijihd.vi.161

Abstract

The present research project aimed to develop a Control release oral Oxcarbazepine tablets by using Polymers like Tamarind gum, Xanthan gum, HPMC K4M, and HPMC K 15M were used for controlling the drug release, and the polymers are mixed in a predetermined ratio. Totally 12 formulations were prepared and evaluated for pre-compression and post-compression parameters, and all the results were found to be within the limits. From the drug and excipients compatibility studies(FT-IR) it was confirmed that the drug and excipients have any interactions. The in vitro dissolution studies revealed that the F12 formulation containing 18% of HPMC K4M & 18% of HPMC K15M controls the drug release up to 12hours. So F12 formulation was considered to be suitable for the formulation of Oxcarbazepine controlled-release tablets at 18% concentration of HPMC K4M & 18% concentration of HPMC K15M and the drug release kinetics revealed that the F12 formulation shows a super case II transport mechanism.

Keywords: Oxcarbazepine, HPMC K4M, HPMC K 15M, Tamarind gum, Xanthan gum, FT-IR

Downloads

Download data is not yet available.

References

Sathish Ummadi, B. Shravani, N. G. Raghavendra Rao, M. Srikanth Reddy, B. Sanjeev Nayak.Overview on Controlled Release Dosage Form. International Journal of Pharma SciencesVol. 3, No. 4 (2013): 258-269.

Brahmankar D.M. and Jaiswal S.B. (1995): “Biopharmaceutics and Pharmacokinetics” a Treatise. Vallabh Prakashan, First Edition; 336-337.

Lachman Leon, Lieberman Herbert A., Kanig Joseph L. (1996) “The Theory and Practice of Industrial Pharmacy” Second edition, Varghese Publishing House; Bombay, 171-196.

Brahmankar DM, Jaiswal SB. Biopharmaceutics and Pharmacokinetics: Pharmacokinetics. 2nd ed. Vallabh Prakashan, Delhi: 2009; 399-401.

John C, Morten C, The Science of Dosage Form Design, Aulton: Modified release peroral dosage forms. 2nd ed. Churchill Livingstone. 2002; 290-300.

Ali Nokhodchi, ShaistaRaja, Pryia Patel, and Kofi Asare-Addo.The Role of Oral Controlled Release Matrix Tablets in Drug Delivery Systems.Bioimpacts. 2012; 2(4): 175–187.

John C, Morten C, The Science of Dosage Form Design, Aulton: Modified release peroral dosage forms. 2nd ed. Churchill Livingstone. 2002; 290-300.

Sathish Ummadi, B. Shravani, N. G. Raghavendra Rao, M. Srikanth Reddy, B. SanjeevNayak.Overview on Controlled Release Dosage Form. International Journal of Pharma Sciences. Vol. 3, No. 4 (2013): 258-269.

Vyas S,P, Khar RK. Controlled Drug delivery: Concepts and Advances. Concepts and Advances.1st ed. Vallabh Prakashan, 2002, p,156-189.

Shargel L, Yu ABC. Modified release drug products. In: Applied Biopharmaceutics and Pharmacokinetics. 4th ed. McGraw Hill.1999; 169-171.

AinleY, Paul JW. Handbook of pharmaceutical excipients. Mongraph 2nd edition. Lodon: PharmaceuticalPress; 2000:51.52, 128, 138-139, 257.113,19.

Indian pharamacopeia. Government ofIndia Ministry Health and Family Welfare. Delhi: Controlerof publication;1996:750,151.

Dollery C. Therapeutic drugs. London: Churchill Livingstone:1991;2:p7-25.

www.drugstore.com.

Hand book of excipients. Second edition. Ainley Wade& PaulJ Weller. American Pharmaceutical Association. Washington.1994.

Lachman Leon, Lieberman HerbertA. Pharmaceutical Dosage Forms:Tablets.In: The Theory and Practice of Industrial Pharmacy. Leaand Febiger, U.S.A, 1991; 3rd edition:293-345.

Subrahmanyam CVS. Textbook of physical pharmaceutics. 2nd edi Delhi: Vallabaprakashan; 2003.p.180-234.

Korsemeyer RW, Peppas NA. Macromolecular and modeling aspects of swelling –controlled Systems. In: Mansdrofsz, RosemanTJ,ad, Controlled Release Delivery systems. New– York,NY: Marcel Dekker; 1983:77.

ICH Q1A (R2) stability testing guidelines: stability testing of new drug substances andproducts. [Online]. 2003 [cited 2008 Nov10]; Availablefrom: URL:http://www.tga.health.gov.au/docs/pdf/euguide/inch/273699r2en.pdf

Reddy KR,Mutalik S,ReddyS.Once-Daily Sustained-Release Matrix Tablets of Nicorandil : Formulation and In Vitro Evaluation. AAPS Pharm Sci Tech.2003; 4(4):article61.

Murali Mohan BabuGV.et.al.,Development of new controlled released formulation of flurbiprofen,in-vitroin-vivo correlation”.Ind J of Pharm Sci 2002 ;64(1):37-43.

NerkurJ, JunHW, ParkJC, ParkMO, Controlled-release matrix tablets of ibuprofen using cellulose ethers and carrageenans: effect of formulation factors on dissolution rates. Eur J Pharm Biopharm 2005 61(1-2)56-68.

Marabathuni VJ, Dinesh P, Ravikumar R, Yamini P, Kiran PS, Hussain SP, Rao CM. Chitosan based sustained release mucoadhesive buccal patches containing amlodipine besylate (AMB). Asian J Res Pharm Sci. 2017 Jun 28;7:97-104.

Marabathuni VJ, Bhavani M, Lavanya M, Padmaja K, Madhavi N, Babu P, Rao CM. Formulation and evaluation of mouth dissolving Tablets of carbamazepine. Magnesium. 2017 Sep 27;15(30):15.